Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.
Earnings beat and guidance raise put Ensign Group in focus
Ensign Group (ENSG) just reported Q2 2026 results and raised its full-year earnings and revenue guidance, putting the stock on many investors' watchlists as they reassess expectations.
The company now guides to 2026 diluted earnings of US$7.75 to US$7.85 per share and revenue of US$5.87b to US$5.92b, citing the strength of second quarter trading as the basis for the higher ranges.
See our latest analysis for Ensign Group.
Ensign Group's recent guidance raise and record Q2 update come after a mixed price backdrop, with the share price up 8.09% over 30 days but down 3.03% over 90 days. Even so, total shareholder return of 17.58% over one year and 112.06% over five years points to a stock that has rewarded long term holders while near term momentum has been more uneven.
If this earnings beat has you looking beyond Ensign Group, it could be a good time to broaden your watchlist and check out 41 healthcare AI stocks
After the post results bounce and guidance upgrade, Ensign Group still trades below both analyst targets and some fair value estimates. Is the discount a sensible reflection of risk, or is caution creating a potential opportunity?
Price-to-earnings of 27.2x: Is it justified for Ensign Group?
On a simple P/E comparison, Ensign Group does not screen as cheap. The stock trades on 27.2x earnings, which sits above both its estimated fair P/E of 25x and the wider US Healthcare industry average of 25.7x.
The P/E ratio compares the current share price to earnings per share. For a company like Ensign Group, which operates skilled nursing, senior living, and related healthcare services, this multiple often reflects what the market is willing to pay today for each dollar of current earnings, given expectations for future profit growth and the perceived resilience of those earnings.
Analysts expect Ensign Group's earnings to grow, although the forecast pace of 12.8% a year is described as not significant in this dataset. That sits alongside a description of current Return on Equity of 15.5% as low and an expected Return on Equity in three years that is still labelled low. Taken together with the stock's P/E premium to the estimated fair P/E level of 25x, this suggests the market is already pricing in a solid earnings profile and quality, rather than a company that is being heavily discounted for risk.
Compared with peers, Ensign Group's 27.2x P/E is above the US Healthcare industry average of 25.7x and also above the estimated fair P/E of 25x that the fair ratio model points to as a potential anchor level. That is a meaningful premium for a company where both revenue and earnings are forecast to grow slower than the broader US market.
Explore the SWS fair ratio for Ensign Group .
Result: Price-to-earnings of 27.2x (OVERVALUED)
However, Ensign Group still faces risks around reimbursement changes and higher operating costs, which could pressure margins and challenge the current P/E premium.
Find out about the key risks to this Ensign Group narrative.
Another view on Ensign Group's value
The P/E workup presents Ensign Group as expensive, yet the SWS DCF model suggests a different perspective. It estimates fair value at US$198.08 per share, which is about 10.1% above the current US$178.16 price and indicates the stock may be trading at a discount instead.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out Ensign Group for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 55 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With sentiment on Ensign Group split between premium pricing and possible undervaluation, it may be useful to review the data yourself as soon as possible. You can start by checking the 4 key rewards .
Looking for more investment ideas beyond Ensign Group?
Do not stop with Ensign Group. The next strong addition to your portfolio could already be on the radar if you take a few minutes to scan other opportunities.
-
Spot potential value opportunities quickly by checking companies highlighted in the 55 high quality undervalued stocks .
-
Strengthen your focus on balance sheet quality by reviewing stocks in the solid balance sheet and fundamentals stocks screener (45 results) .
-
Seek out underfollowed opportunities with robust fundamentals through the screener containing 19 high quality undiscovered gems .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ENSG .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
